ADIL
What one share of Adial Pharmaceuticals holds
Pharmaceutical Preparations
We have devoted the vast majority of our resources to development efforts relating to AD04, including preparation for and conducting clinical trials, providing general and administrative support for these operations and protecting our intellectual property.
Adial Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$28.91 |
|---|---|
| Cash and investments | $10.93 |
| Book value | −$14.61 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$545.00 | — | −$402.09 | — | $430.43 |
| 2020 | — | −$546.26 | — | −$382.79 | — | $173.09 |
| 2021 | — | −$653.06 | $2.17 | −$403.94 | — | $104.66 |
| 2022 | — | −$317.81 | — | −$279.23 | — | $76.73 |
| 2023 | — | −$89.90 | — | −$119.45 | — | $61.37 |
| 2024 | — | −$68.01 | — | −$35.67 | — | $15.72 |
| 2025 | — | −$11.93 | — | −$9.71 | — | $4.75 |